ESR1 and breast cancer: A comparatively high expression of the androgen receptor (AR) within this subgroup of ER-negative samples (P = 4*10-44, t-test; Figure S4 in Additional file 3) suggested these cases to be of the apocrine breast cancer subtype [38].